Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies

Yazmin Odia

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-Oncology Advances
Volume	4
State	Published - Jan 1 2022

Cite this

@article{071f7c4c51de4677bd8f598869aa612c,

title = "Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies",

author = "Yazmin Odia",

note = "Neurooncol Adv (2022) 4(1):vdac012",

year = "2022",

month = jan,

day = "1",

language = "American English",

volume = "4",

journal = "Neuro-Oncology Advances",

}

TY - JOUR

T1 - Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies

AU - Odia, Yazmin

N1 - Neurooncol Adv (2022) 4(1):vdac012

PY - 2022/1/1

Y1 - 2022/1/1

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/4401

M3 - Article

VL - 4

JO - Neuro-Oncology Advances

JF - Neuro-Oncology Advances

ER -

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies

Other files and links

Cite this